153 related articles for article (PubMed ID: 36115922)
21. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.
Meyerhoff RR; Yang CF; Speicher PJ; Gulack BC; Hartwig MG; D'Amico TA; Harpole DH; Berry MF
J Surg Res; 2015 Jun; 196(1):23-32. PubMed ID: 25791825
[TBL] [Abstract][Full Text] [Related]
22. How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?
Sharkey AJ; O'Byrne KJ; Nakas A; Tenconi S; Fennell DA; Waller DA
Lung Cancer; 2016 Oct; 100():5-13. PubMed ID: 27597274
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
24. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
Linton A; Pavlakis N; O'Connell R; Soeberg M; Kao S; Clarke S; Vardy J; van Zandwijk N
Br J Cancer; 2014 Oct; 111(9):1860-9. PubMed ID: 25188323
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: an institutional experience in Turkey.
Kucukoner M; Ali Kaplan M; Inal A; Urakci Z; Abakay O; Cetin Tanrikulu A; Abakay A; Selim Sen H; Turkcu G; Senyigit A; Buyukbayram H; Isikdogan A
J BUON; 2014; 19(1):164-70. PubMed ID: 24659659
[TBL] [Abstract][Full Text] [Related]
26. Systemic treatment in patients with malignant pleural mesothelioma - real life experience.
Ziółkowska B; Cybulska-Stopa B; Papantoniou D; Suwiński R
BMC Cancer; 2022 Apr; 22(1):432. PubMed ID: 35443624
[TBL] [Abstract][Full Text] [Related]
27. PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy.
Bitanihirwe BK; Meerang M; Friess M; Soltermann A; Frischknecht L; Thies S; Felley-Bosco E; Tsao MS; Allo G; de Perrot M; Seifert B; Moch H; Stahel R; Weder W; Opitz I
J Thorac Oncol; 2014 Feb; 9(2):239-47. PubMed ID: 24419422
[TBL] [Abstract][Full Text] [Related]
28. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
Kircheva DY; Husain AN; Watson S; Kindler HL; Durkin A; Vigneswaran WT
Eur J Cardiothorac Surg; 2016 Jun; 49(6):1642-7. PubMed ID: 26802143
[TBL] [Abstract][Full Text] [Related]
29. Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
Shaikh F; Zauderer MG; von Reibnitz D; Wu AJ; Yorke ED; Foster A; Shi W; Zhang Z; Adusumilli PS; Rosenzweig KE; Krug LM; Rusch VW; Rimner A
J Thorac Oncol; 2017 Jun; 12(6):993-1000. PubMed ID: 28341225
[TBL] [Abstract][Full Text] [Related]
30. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.
Hoda MA; Dong Y; Rozsas A; Klikovits T; Laszlo V; Ghanim B; Stockhammer P; Ozsvar J; Jakopovic M; Samarzija M; Brcic L; Bendek M; Szirtes I; Reid G; Kirschner MB; Kao SC; Opitz I; Weder W; Frauenfelder T; Nguyen-Kim TD; Aigner C; Klepetko W; van Zandwijk N; Berger W; Dome B; Grusch M; Hegedus B
Eur J Cancer; 2016 Aug; 63():64-73. PubMed ID: 27288871
[TBL] [Abstract][Full Text] [Related]
31. Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma.
Alchami FS; Attanoos RL; Bamber AR
J Clin Pathol; 2017 Feb; 70(2):179-182. PubMed ID: 27798081
[TBL] [Abstract][Full Text] [Related]
32. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Popat S; Curioni-Fontecedro A; Dafni U; Shah R; O'Brien M; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Nadal E; Janthur WD; López Castro R; García Campelo R; Rusakiewicz S; Letovanec I; Polydoropoulou V; Roschitzki-Voser H; Ruepp B; Gasca-Ruchti A; Peters S; Stahel RA
Ann Oncol; 2020 Dec; 31(12):1734-1745. PubMed ID: 32976938
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
Lim JH; Choi JY; Im Y; Yoo H; Jhun BW; Jeong BH; Park HY; Lee K; Kim H; Kwon OJ; Han J; Ahn MJ; Kim J; Um SW
PLoS One; 2020; 15(2):e0229299. PubMed ID: 32069313
[TBL] [Abstract][Full Text] [Related]
34. Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma.
Bilecz A; Stockhammer P; Theegarten D; Kern I; Jakopovic M; Samarzija M; Klikovits T; Hoda MA; Döme B; Oberndorfer F; Muellauer L; Fillinger J; Kovács I; Pirker C; Schuler M; Plönes T; Aigner C; Klepetko W; Berger W; Brcic L; Laszlo V; Hegedus B
Histopathology; 2020 Jul; 77(1):55-66. PubMed ID: 32170970
[TBL] [Abstract][Full Text] [Related]
35. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy Versus Supportive Care for Unresected Malignant Pleural Mesothelioma.
Verma V; Wegner RE; Brooks ED; Miccio JA; Kann BH; Finley GG; Raj MS; Grover S; Mohindra P; Simone CB
Clin Lung Cancer; 2019 Jul; 20(4):263-269. PubMed ID: 30992187
[TBL] [Abstract][Full Text] [Related]
37. Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma.
Meerang M; Bérard K; Friess M; Bitanihirwe BK; Soltermann A; Vrugt B; Felley-Bosco E; Bueno R; Richards WG; Seifert B; Stahel R; Weder W; Opitz I
Mol Oncol; 2016 Oct; 10(8):1255-65. PubMed ID: 27378628
[TBL] [Abstract][Full Text] [Related]
38. CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness.
Inaguma S; Lasota J; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Schrump DS; Hassan R; Kasai K; Miettinen M; Ikeda H
J Pathol; 2020 Feb; 250(2):205-216. PubMed ID: 31639216
[TBL] [Abstract][Full Text] [Related]
39. Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal.
Pelosi G; Papotti M; Righi L; Rossi G; Ferrero S; Bosari S; Calabrese F; Kern I; Maisonneuve P; Sonzogni A; Albini A; Harari S; Barbieri F; Capelletto E; Catino AM; Cavone D; De Palma A; Fusco N; Lunardi F; Maiorano E; Marzullo A; Novello S; Papanikolaou N; Pasello G; Pennella A; Pezzuto F; Punzi A; Prisciandaro E; Rea F; Rosso L; Scattone A; Serio G
J Thorac Oncol; 2018 Nov; 13(11):1750-1761. PubMed ID: 30249391
[TBL] [Abstract][Full Text] [Related]
40. Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma.
Cornelissen R; Lievense LA; Maat AP; Hendriks RW; Hoogsteden HC; Bogers AJ; Hegmans JP; Aerts JG
PLoS One; 2014; 9(9):e106742. PubMed ID: 25192022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]